[1] |
BOKEMEYER C, BONDARENKO I, HARTMAN JT, et al.Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer:the OPUS study[J].Ann Oncol, 2011, 22(7):1535. doi: 10.1093/annonc/mdq632 |
[2] |
GARDE NOGUERA J, JANTUS-LEWINTRE E, GIL-RAGA M, et al.Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab:a retrospective analysis[J].Mol Clin Oncol, 2017, 6(3):403. doi: 10.3892/mco.2017.1149 |
[3] |
GARCÍA-ALFONSO P, GRANDE E, POLO E, The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to KRAS status[J].Angiogenesis, 2014, 17(4):805. doi: 10.1007/s10456-014-9433-6 |
[4] |
朱晓丽, 蔡旭, 张玲, 等.中国结直肠癌患者中KRAS与BRAF基因突变特征及其临床病理相关性[J].中国病理学杂志, 2012, 41(9):584. |
[5] |
KIM ST, PARK KH, SHIN SW, et al. Dose KRAS mutation status affect on the effect of VEGF therapy in metastatic colon cancer patients?[J]. Cancer Res Treat, 2014, 46(1):48. doi: 10.4143/crt.2014.46.1.48 |
[6] |
MAUGHAN TS, ADAMS RA, SMITH CG, et al.Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer:results of the randomised phase 3 MRC COIN trial[J].Lancet, 2011, 377(9783):2103. doi: 10.1016/S0140-6736(11)60613-2 |
[7] |
VALE CL, TIERNEY JF, FISHER D, et al.Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis[J].Cancer Treat Rev, 2012, 38(6):618. doi: 10.1016/j.ctrv.2011.11.002 |
[8] |
PRICE TG, HARDINGHAM JE, LEE CK, et al.Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase Ⅲ AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer[J].Clin Oncol, 2011, 29(19):2675. doi: 10.1200/JCO.2010.34.5520 |
[9] |
HURWITZ HI, YI J, INCE W, et al.The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status:analysis of a phase Ⅲ study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer[J].Oncologist, 2009, 14(1):22. doi: 10.1634/theoncologist.2008-0213 |
[10] |
NORGUET E, DAHAN L, GAUDART J, et al.Cetuximab after bevacizumab in metastatic colorectal cancer:is it the best sequence?[J].Dig Liver Dis, 2011, 43(11):917. doi: 10.1016/j.dld.2011.06.002 |
[11] |
BASSO M, STRIPPOLI A, ORLANDI A, et al.KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastaticcolorectal cancer patients[J].Br J Cancer, 2013, 108(1):115. doi: 10.1038/bjc.2012.526 |
[12] |
PRICE TJ, HARDINGHAM JE, LEE CK, et al.Impact of KRAS and BRAF gene mutation status on outcomes from the Phase Ⅲ AGITG MAX Trial of capecitabine alone or in Combination with bevacizumab and mitomycin in advanced colorectal cancer[J].J Clin Oncol, 2011, 29(19):2675. doi: 10.1200/JCO.2010.34.5520 |
[13] |
BRUDVIK KW, KOPETZ SE, LI L, et al.Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases[J].Br J Surg, 2015, 102(10):1175. doi: 10.1002/bjs.2015.102.issue-10 |
[14] |
KARAPETIS CS, KHAMBATA-FORD S, JONKER DJ, et al.KRAS mutations and benefit from cetuximab in advanced colorectal cancer[J].N Engl J Med, 2008, 359:1757. doi: 10.1056/NEJMoa0804385 |
[15] |
REINACHER-SCHICK A, SCHULMANN K, MODEST DP, et al.Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy:results from a translational study of the AIO colorectal study group[J].BMC Cancer, 2012, 12(6):349. |